Tranylcypromine/trifluoperazine explained

Tranylcypromine/trifluoperazine (brand names Parstelin, Parmodalin, Jatrosom N, Stelapar) is a combination formulation of the monoamine oxidase inhibitor antidepressant drug tranylcypromine and the typical antipsychotic drug trifluoperazine that has been used in the treatment of major depressive disorder.^{[1] [2] [3]} It contains 10 mg tranylcypromine and 1 mg trifluoperazine.^[4] The drug has been in clinical use since at least 1961.

It may come to assume a certain place in the treatment of borderline personality disorder.^[5]

See also

• Amitriptyline/perphenazine
• Flupentixol/melitracen
• Olanzapine/fluoxetine

Notes and References

1. Book: Dart RC . Monoamine Oxidase Inhibitors . Medical Toxicology. https://books.google.com/books?id=BfdighlyGiwC&pg=PA825 . 2004 . Lippincott Williams & Wilkins . 978-0-7817-2845-4 . 825–.
2. Book: Stahl SM . Prescriber's Guide: Stahl's Essential Psychopharmacology. 15 May 2014. Cambridge University Press. 978-1-107-67502-5. 783–.
3. Straker M, Grauer H . Clinical Study of a Potent Antidepressant, Tranylcypromine with Trifluorperazine (Parstelin), in the Aged Chronically Ill . Canadian Medical Association Journal . 85 . 3 . 127–130 . July 1961 . 20326829 . 1848140 .
4. Book: Kalinowsky LB, Hippius H, Klein HE . Biological Treatments in Psychiatry. 1982. Grune and Stratton, Harcourt Brace Jovanovich. 978-0-8089-1423-5.
5. Cowdry, R. W., & Gardner, D. L. (1988). Pharmacotherapy of borderline personality disorder. Alprazolam, carbamazepine, trifluoperazine, and tranylcypromine. Archives of general psychiatry, 45(2), 111–119. https://doi.org/10.1001/archpsyc.1988.01800260015002